immunotherapy

December 20, 2018
Richard L. Schilsky, MD, FACP, FSCT, FASCO

Tumor-Agnostic Treatment for Cancer: An Expert Perspective

English
Richard.Schilsky

Some recent FDA approvals have made many people aware of tumor-agnostic treatments. But what does that mean and how could it benefit someone with cancer? ASCO Chief Medical Officer Richard L. Schilsky gives insight into this new way of thinking about cancer treatment.

Read More >>

Pages

Subscribe to RSS - immunotherapy